Back to Search Start Over

Aberrant Induction of a Mesenchymal/Stem Cell Program Engages Senescence in Normal Mammary Epithelial Cells.

Authors :
Bryson BL
Tamagno I
Taylor SE
Parameswaran N
Chernosky NM
Balasubramaniam N
Jackson MW
Source :
Molecular cancer research : MCR [Mol Cancer Res] 2021 Apr; Vol. 19 (4), pp. 651-666. Date of Electronic Publication: 2020 Dec 22.
Publication Year :
2021

Abstract

Although frequently associated with tumor progression, inflammatory cytokines initially restrain transformation by inducing senescence, a key tumor-suppressive barrier. Here, we demonstrate that the inflammatory cytokine, oncostatin M, activates a mesenchymal/stem cell (SC) program that engages cytokine-induced senescence (CIS) in normal human epithelial cells. CIS is driven by Snail induction and requires cooperation between STAT3 and the TGFβ effector, SMAD3. Importantly, as cells escape CIS, they retain the mesenchymal/SC program and are thereby bestowed with a set of cancer SC (CSC) traits. Of therapeutic importance, cells that escape CIS can be induced back into senescence by CDK4/6 inhibition, confirming that the mechanisms allowing cells to escape senescence are targetable and reversible. Moreover, by combining CDK4/6 inhibition with a senolytic therapy, mesenchymal/CSCs can be efficiently killed. Our studies provide insight into how the CIS barriers that prevent tumorigenesis can be exploited as potential therapies for highly aggressive cancers. IMPLICATIONS: These studies reveal how a normal cell's arduous escape from senescence can bestow aggressive features early in the transformation process, and how this persistent mesenchymal/SC program can create a novel potential targetability following tumor development.<br /> (©2020 American Association for Cancer Research.)

Details

Language :
English
ISSN :
1557-3125
Volume :
19
Issue :
4
Database :
MEDLINE
Journal :
Molecular cancer research : MCR
Publication Type :
Academic Journal
Accession number :
33443106
Full Text :
https://doi.org/10.1158/1541-7786.MCR-19-1181